MedTrace Logo

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

NCT02142036 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-03-13

No results posted yet for this study

Summary

The metastatic lesions may be very different from the primary tumor because of intrinsic tumor heterogenity, clonal selection through metastatic process and following previous cytotoxic treatments. Metastatic tumor harboring actionable targets or signaling pathways may respond to inhibitory agents directed against specific aberrations irrespective of tumor origin. In the MetAction study, patients will receive therapy based on molecular aberrations in the metastatic lesions, actionable target identification (ATI), rather than on histological tumor type.

The ATI rate in an unselected metastatic patient population is uncertain, and response rates associated with ATI based targeted therapy have hardly been reported. In this perspective, The MetAction study is essentially a feasibility study aiming to tailor metastatic cancer therapy based on genomic profiles.

Conditions

Interventions

DRUG

EMA-approved ATI based targeted therapy

All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.

Sponsors & Collaborators

  • The Research Council of Norway

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Kjersti Flatmark, MD PhD · Oslo University Hospital

  • Svein Dueland, MD · Oslo University Hospital

  • Anne Hansen Ree, Prof. MD PhD · University Hospital, Akershus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02142036 on ClinicalTrials.gov